phosphorylcholine has been researched along with Carcinoma in 13 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis." | 9.09 | Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
| "Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis." | 5.09 | Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
| " Human HT29 (colon) and MDA-MB-231 (breast) carcinoma cells were examined by proton (1H) and phosphorus (31P) magnetic resonance spectroscopy (MRS) before and after treatment with MN58b both in culture and in xenografts." | 3.73 | Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. ( Al-Saffar, NM; Chung, YL; Griffiths, JR; Jackson, LE; Judson, IR; Lacal, JC; Leach, MO; Madhu, B; Ramírez de Molina, A; Troy, H; Workman, P, 2006) |
| "Perifosine could potently inhibit thyroid cancer cell growth when used alone, but a strong antagonism occurred between this drug and PLX4032 or AZD6244 in the inhibition of thyroid cancer cell growth with all combination index values higher than 1." | 1.38 | The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. ( Liu, D; Liu, R; Xing, M, 2012) |
| " In rats, the LD50 of HPC was 606 mumol/kg; the maximum tolerable dose over four weeks was 39 mumol/kg." | 1.27 | Alkyl phosphocholines: toxicity and anticancer properties. ( Berger, MR; Eibl, HJ; Garzon, FT; Muschiol, C; Scherf, HR; Schmähl, D; Schuler, B; Unger, C; Zeller, WJ, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 6 (46.15) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Engel, JB | 1 |
| Schönhals, T | 1 |
| Häusler, S | 1 |
| Krockenberger, M | 1 |
| Schmidt, M | 1 |
| Horn, E | 1 |
| Köster, F | 1 |
| Dietl, J | 1 |
| Wischhusen, J | 1 |
| Honig, A | 1 |
| Liu, R | 1 |
| Liu, D | 1 |
| Xing, M | 1 |
| Beil, M | 1 |
| Micoulet, A | 1 |
| von Wichert, G | 1 |
| Paschke, S | 1 |
| Walther, P | 1 |
| Omary, MB | 1 |
| Van Veldhoven, PP | 1 |
| Gern, U | 1 |
| Wolff-Hieber, E | 1 |
| Eggermann, J | 1 |
| Waltenberger, J | 1 |
| Adler, G | 1 |
| Spatz, J | 1 |
| Seufferlein, T | 1 |
| Al-Saffar, NM | 1 |
| Troy, H | 1 |
| Ramírez de Molina, A | 1 |
| Jackson, LE | 1 |
| Madhu, B | 1 |
| Griffiths, JR | 1 |
| Leach, MO | 1 |
| Workman, P | 1 |
| Lacal, JC | 1 |
| Judson, IR | 1 |
| Chung, YL | 1 |
| Galons, JP | 1 |
| Job, C | 1 |
| Gillies, RJ | 2 |
| Spruss, T | 1 |
| Bernhardt, G | 1 |
| Schönenberger, H | 1 |
| Engel, J | 1 |
| Bhujwalla, ZM | 1 |
| Aboagye, EO | 1 |
| Chacko, VP | 1 |
| Mendola, CE | 1 |
| Backer, JM | 1 |
| Konstantinov, SM | 1 |
| Berger, MR | 2 |
| Clive, S | 1 |
| Gardiner, J | 1 |
| Leonard, RC | 1 |
| Rümenapp, U | 1 |
| Lümmen, G | 1 |
| Virchow, S | 1 |
| Hanske, J | 1 |
| Meyer zu Heringdorf, D | 1 |
| Jakobs, KH | 1 |
| Naundorf, H | 1 |
| Rewasowa, EC | 1 |
| Fichtner, I | 1 |
| Büttner, B | 1 |
| Becker, M | 1 |
| Görlich, M | 1 |
| Muschiol, C | 1 |
| Schuler, B | 1 |
| Scherf, HR | 1 |
| Garzon, FT | 1 |
| Zeller, WJ | 1 |
| Unger, C | 1 |
| Eibl, HJ | 1 |
| Schmähl, D | 1 |
| Berman, S | 1 |
| Gewurz, H | 1 |
| Mold, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fluorescent Nanoparticles Conjugated Long-acting Somatostatin Analog for Potent Suppression and Bioimaging Breast Cancer[NCT04138342] | Phase 1 | 30 participants (Anticipated) | Interventional | 2019-09-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for phosphorylcholine and Carcinoma
| Article | Year |
|---|---|
Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Br | 1999 |
12 other studies available for phosphorylcholine and Carcinoma
| Article | Year |
|---|---|
Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2011 |
The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma; Cell Proliferation; Down- | 2012 |
Sphingosylphosphorylcholine regulates keratin network architecture and visco-elastic properties of human cancer cells.
Topics: Actin Cytoskeleton; Carcinoma; Cell Movement; Cell Size; Cytoskeleton; Elasticity; Fluorescent Antib | 2003 |
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Butanes; Carcinoma; Choline Kin | 2006 |
Increase of GPC levels in cultured mammalian cells during acidosis. A 31P MR spectroscopy study using a continuous bioreactor system.
Topics: 3T3 Cells; Acidosis; Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Cell Line; Cell Line, Transformed | 1995 |
Antitumour activity of miltefosine alone and after combination with platinum complexes on MXT mouse mammary carcinoma models.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug | 1993 |
Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Ethanolamines; Female; Genetic Vectors; Gly | 1999 |
Human urinary bladder carcinoma cell lines respond to treatment with alkylphosphocholines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; DNA Damage; DNA Fragmentation; DNA, Neoplasm; Enzyme-Li | 1999 |
Sphingolipid receptor signaling and function in human bladder carcinoma cells: inhibition of LPA- but enhancement of thrombin-stimulated cell motility.
Topics: Actins; Calcium; Carcinoma; Cell Division; Cell Movement; Cyclic AMP; GTP-Binding Proteins; Humans; | 2000 |
Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Drug Screening Assays, A | 1992 |
Alkyl phosphocholines: toxicity and anticancer properties.
Topics: Animals; Antineoplastic Agents; Carcinoma; Choline; Dose-Response Relationship, Drug; Female; Male; | 1987 |
Binding of C-reactive protein to nucleated cells leads to complement activation without cytolysis.
Topics: Animals; Antibodies, Neoplasm; Binding Sites, Antibody; C-Reactive Protein; Carcinoma; Cell Line; Co | 1986 |